Mission Statement, Vision, & Core Values (2026) of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) stands at the forefront of China's biotech industry, founded in 1991 and headquartered in Beijing's Zhongguancun Life Science Park, where its R&D-driven culture fuels a product portfolio of diagnostic reagents and vaccines for infectious diseases including hepatitis, HIV, syphilis, influenza and tuberculosis; recognized as a top Chinese brand in the blood banking sector for HIV and hepatitis diagnostics and operating within the Yangshengtang Group, Wantai ties a mission of 'Advancing Human Health Through Biotechnology' to a vision of becoming a respected, industry-leading healthcare manufacturer while its core values - science-driven research, uncompromising quality, continuous innovation, social responsibility, and global partnership - guide ongoing expansion of reliable healthcare solutions worldwide.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) - Intro

• Founded: 1991; Headquarters: Zhongguancun Life Science Park, Beijing.
• Parent / Group: Operates under the Yangshengtang Group network.
• Core focus: In-vitro diagnostics (IVD) and vaccine R&D & production.

• Major diagnostic areas: Hepatitis (B/C), HIV, syphilis, influenza, TB.
• Target customers: Blood banks, hospitals, public health labs, commercial testing labs.
• Global reach: Export and cooperation networks spanning dozens of countries.

• Mission: Develop reliable, high-quality diagnostics and vaccines that protect public health and improve clinical outcomes through accessible, scientifically driven products.
• Vision: Be a globally respected Chinese biopharma innovator, advancing disease prevention and diagnostics through continuous technology leadership and international collaboration.
• Core values:
  • Science-led innovation - prioritize rigorous R&D and evidence-based product development.
  • Quality & compliance - maintain high manufacturing standards and regulatory adherence (GMP/ISO/other certifications).
  • Patient & public health focus - design solutions addressing clinical and epidemiologic needs.
  • Partnership & responsibility - collaborate with health systems, academia, and global partners while upholding corporate responsibility.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) - Overview

• Core emphasis on translating cutting-edge science into reliable diagnostic and therapeutic products.
• Commitment to accessibility - ensuring solutions reach diverse populations domestically and internationally.
• Dual focus on innovation (novel assays, platforms) and operational quality (manufacturing, regulatory compliance).

• Product pipeline and commercial portfolio aligned with public-health impact: infectious disease diagnostics, immunodiagnostics, and related reagents and instruments.
• Consistent reinvestment into R&D and manufacturing scale-up to convert scientific advances into market-ready products.
• Active role in epidemic response and large-scale screening programs, demonstrating mission alignment in crisis settings.

• Prioritization of pathogen detection platforms and immunoassays that have direct population health benefits (screening, surveillance, clinical diagnostics).
• Investment in scalable manufacturing to ensure supply reliability during surges in demand (e.g., epidemic response).
• Collaborations with academic, public-health, and industrial partners to accelerate translation from bench to bedside.

• Focus on enhancing diagnostic accessibility in lower-resource settings via cost-effective reagents and robust point-of-care formats.
• Building platform technologies that can be rapidly adapted to emerging pathogens and immune-monitoring needs.
• Maintaining quality systems and regulatory readiness to support rapid deployment without compromising safety or performance.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) - Mission Statement

• Commit to high-quality, clinically validated diagnostics and biologics that meet regulatory and clinical requirements.
• Expand access to essential testing and therapeutic solutions through reliable manufacturing capacity and distribution networks.
• Invest in R&D to drive innovation in diagnostics, vaccines and biologics, translating science into scalable products.
• Build long-term partnerships with healthcare providers, research institutions and global distributors to enhance impact and reputation.

• Brand leadership: prioritize clinical performance and post-market surveillance to ensure trust among clinicians and patients.
• Industry reputation: adopt international quality standards (e.g., GMP, CE/IVD registrations where applicable) and transparent corporate governance.
• Long-term growth: diversify product portfolio across diagnostics, reagents, vaccines and biologics while pushing global market access.
• R&D commitment: sustained investment in platforms that enable rapid response to emerging infectious diseases and chronic-condition diagnostics.

• Quality and compliance: sustained investment in GMP facilities, quality control labs and regulatory dossiers to support international registrations.
• Scale and capacity: manufacturing scale-up for reagents and diagnostic kits to meet both domestic demand and export opportunities.
• Scientific leadership: partnerships with academic and clinical centers to validate assays and support evidence-based adoption.
• Market reputation: active post-market monitoring and customer support to maintain clinician and patient trust.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) - Vision Statement

• Rooted in Science, Committed to Health: Prioritizing evidence‑based research and translational science to advance diagnostics and biologics for viral, hepatic, and immunological diseases.
• Built on Quality, Powered by Innovation: Sustaining ISO and GMP‑aligned production with continuous product lifecycle innovation to meet evolving clinical and public‑health needs.
• Quality at the Core, Customers at Heart: Ensuring product reliability through batch traceability, external quality assessments, and post‑market surveillance to protect patient safety and clinician trust.
• Continuous Innovation, Sustainable Progress: Investing in iterative R&D and platform technologies to enable long‑term, sustainable growth while reducing environmental footprint across manufacturing and distribution.
• Social Responsibility, Building the Future Together: Committing to equitable access, public‑health collaborations, and community engagement to strengthen health systems-especially in low‑ and middle‑income regions.
• Global Partnership: Seeking strategic alliances with WHO, international diagnostic networks, academic institutions, and commercial partners to scale impact and harmonize standards.

• Scale high‑quality manufacturing capacity to reduce lead times and meet surge demand during epidemics and routine screening programs.
• Increase certified international partnerships and regulatory approvals (CE, WHO EUL, and equivalents) to expand market access and interoperability.
• Allocate sustained R&D resources toward platform technologies (e.g., high‑throughput serology, point‑of‑care molecular assays, and next‑generation reagents) to diversify product pipelines.
• Enhance post‑market data collection and real‑world evidence programs to strengthen product performance claims and customer support.
• Embed sustainability metrics (energy, waste, water) into site operations to align growth with environmental stewardship and corporate social responsibility.

• Strategic alliances with international health organizations and academic centers to co‑develop assays, validate performance, and support field implementation.
• Commercial collaborations to localize manufacturing or distribution, shortening supply chains and improving affordability.
• Transparency in reporting clinical performance, regulatory status, and manufacturing practices to build global trust in products and programs.